CASP3 and neoplasm: Despite the blockade of JNK activation by the combined use of SP600125 and lapatinib, we did not observe an increased benefit of using both inhibitors either in vitro by Caspase-3 activity assay (Fig 2D) or in vivo by tumor analysis (Fig 2E).